The latest in policy & regulation: 6 developments from the past day, tracked and curated by the HealthTech Cube news desk. The lead story: PMOS Care, Smart Textiles, Online Research Ethics, and the TEMPO Pilot.
Pfizer Pill’s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions
Pfizer’s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during European Academy of Dermatology and Venereology annual meeting. If Pfizer’s daily pill is approved, it would compete against an Incyte topical cream that is currently the only FDA-approved therapy for this autoimmune skin disorder. The post Pfizer Pill’s Pha…
Follow the full firehose on the HTC Wire, refreshed automatically every day.
Reach the people behind these stories. HealthTech Cube demand gen programs deliver qualified healthcare technology leads from $49.50 per lead - see packages or download the 2026 media kit.